Layoffs are now confirmed: legit link included!

Quote












Another truly sad day... This makes me sick to my stomach. Nobody wanted to believe me when I said "something" was happening on 9/13.... That Jimenez was gonna be talking to investors,etc.
 


















Anonymous said:
If u would read further he refers to hr,it,fiance dept
Click to expand...

Keeping reading....he makes reference to sales too. No one is safe! Well, it's that time of the year so not surprising. Cardio people won't be as lucky as last year with Diovan just months away from going generic. As soon as that happens, Exforge follows by default. What's in your wallet??
 






Its funny that you all needed a "link" or someone on CP to confirm layoffs are coming or will be here in the near future. Two simple things should have let you know this is happening
1) Diovan off patent
2) This is big pharma

I only hope you approach your personal life with more brains and business sense than you do your careers.
 


















Once again this is not any new information. It does not mention sales and marketing layoffs. The reference is to cuts made in 2010 Q4. Im not saying they wont do it again in 2011 Q4, its just not in this BS thread.
 












WAKE UP YOU IDIOT!!!!!

By Tracy Staton Comment | Forward | Twitter | Facebook | LinkedIn

Fresh off his promises that this year's round of cost-cutting would top last year's $1.9 billion, Novartis ($NVS) CEO Joe Jimenez (photo) gave the Swiss newspaper Handelszeitung some hints about what operations might face the axe. Jimenez has his eyes on cutbacks in sales and marketing and in manufacturing, as Dow Jones reports.

"We have spent too much money on marketing and selling our drugs," Jimenez told the paper (as quoted by Dow Jones). And even though the company has already made cuts in those areas, the CEO believes Novartis can streamline further. "We can save even more, even if we grow. This business revolves around science, not around marketing."

Those are words sure to frighten Novartis marketing and sales folks, who've already absorbed hundreds of layoffs. The Swiss drugmaker cut its sales force by 1,400 last year in the U.S. as it shifts focus from mass-market medicines to specialty drugs. But the company's manufacturing operations could see some big changes, too. Cuts there could mean that underperforming plants are shut down completely.

"We have 83 factories and we only use about 50% to full capacity--that isn't good," Jimenez said. "We should identify centers of excellence, and consolidate our manufacturing."

One area that appears to be safe is R&D. Remember what Jimenez said about the science? With that in mind, he may even boost R&D spending over the next 5 years, he said.

- read the Dow Jones coverage
- get the Handelszeitung story (in German)
 






Top Bottom
Back
Quote